ClinicalTrials.gg
RecruitingNCT07560878SyncTUpdated May 13, 2026

Synaptic Mechanisms of Continuous Theta Burst Stimulation in Depression

An Early Phase 1 interventional study of D-Cycloserine (DCS) and Continuous theta-burst stimulation (cTBS) in Major Depression, sponsored by Mclean Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Mclean Hospital · Early Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies testing cycloserine in Depressive Disorder, Major — 2 open to participants now, 3 under way, none of them phase 3. Cycloserine · Depressive Disorder, Major.

Planned enrollment
4th of 10
80 · median 43
Started
2026
with 1 other
Phase 1
3 of 10
1 open now
Registered
10th of 10
by date
Lead sponsor
2 of 10
Mclean Hospital

Among the 10 studies testing cycloserine in Depressive Disorder, Major, this one is the 4th largest by planned enrollment, is one of 2 that started in 2026, is one of 3 in phase 1, and was the 10th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

2 of the 10 studies testing cycloserine in Depressive Disorder, Major are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About cycloserine

Cycloserine: first FDA approval 1964 (SEROMYCIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing cycloserine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

Many people with depression do not get better with standard treatments like medication. One promising alternative is transcranial magnetic stimulation (TMS), a non-invasive procedure that uses magnetic pulses to stimulate specific brain regions. A particular pattern of TMS called continuous theta-burst stimulation (cTBS) is thought to reduce overactive brain activity in depression, but the investigators do not yet fully understand how it works at the level of brain cells and connections.

This study aims to determine the biological mechanism by which cTBS changes brain activity in people with depression. Specifically, the investigators are testing two competing ideas: (1) that cTBS works by weakening the connections between brain cells through a process called long-term depression (LTD), which is driven by a chemical messenger system called glutamate; or (2) that cTBS works by increasing the brain's natural "braking" system, driven by a different chemical messenger called GABA.

To test these ideas, participants with depression will receive cTBS along with one of four FDA-approved medications, or placebo, that either boost or block these chemical messenger systems. The investigators will measure changes in brain activity using electroencephalography (EEG) recorded simultaneously with TMS. Specific patterns in the EEG signal, called TMS-evoked potentials (TEPs), act as a window into how different brain cell types are responding to stimulation.

Each participant will complete four study visits, each testing a different drug-TMS combination in random order. One group of participants will test drugs targeting the glutamate system (d-cycloserine and memantine). A second group will test drugs targeting the GABA system (lorazepam and baclofen). All drugs are given as a single oral dose and are commonly used in clinical practice.

Understanding exactly how cTBS works at a biological level could open the door to more effective, personalized TMS treatments.

Read the detailed description

Major depressive disorder (MDD) affects an estimated 280 million people worldwide, and a substantial proportion do not respond adequately to first-line pharmacological treatments. Continuous theta-burst stimulation (cTBS) is a widely used form of repetitive transcranial magnetic stimulation (rTMS) that quiets targeted brain networks, and holds particular promise for patients who are not well-served by conventional excitatory TMS protocols due to safety or tolerability concerns. Despite its common clinical use, the synaptic mechanisms by which cTBS works remain poorly characterized, limiting systematic efforts to improve its efficacy.

Two mechanistic hypotheses have been proposed. The first is that cTBS induces LTD-like synaptic depression through NMDA receptor (NMDAR)-dependent mechanisms, analogous to the low-frequency stimulation protocols that produce AMPA receptor internalization and synapse weakening in animal models. Evidence for this comes from studies in the healthy motor cortex demonstrating that cTBS-induced corticomotor inhibition is blocked by NMDAR antagonists. The second hypothesis is that cTBS works through GABA receptor-mediated inhibition, either via GABA-A receptors reducing signal propagation through membrane hyperpolarization, or GABA-B receptors suppressing presynaptic neurotransmitter release. Whether GABAergic mechanisms contribute to cTBS effects has not been directly tested, and these hypotheses are not mutually exclusive.

Critically, all prior mechanistic evidence comes from the motor cortex in healthy volunteers. The dorsolateral prefrontal cortex (dlPFC), the clinical target for depression, differs substantially from motor cortex in anatomy, interindividual variability, and plasticity. Depression itself is associated with reduced synaptic plasticity, including reduced expression of NMDAR subunits and synapse-related genes in postmortem prefrontal tissue. Whether cTBS mechanism established in healthy motor cortex translates to the depressed dlPFC cannot be assumed, and has not been tested. Furthermore, whether cTBS-induced inhibition can be pharmacologically enhanced remains entirely unexplored.

This study uses a randomized, double-blind, placebo-controlled crossover design to directly test NMDAR- and GABA receptor-mediated contributions to cTBS-induced plasticity in the dlPFC of individuals with MDD. Participants are assigned to one of two parallel aims. Aim 1 tests glutamatergic mechanisms: participants complete four visits receiving cTBS paired with placebo, d-cycloserine (DCS), or memantine (MEM), with two placebo visits. Aim 2 tests GABAergic mechanisms: participants complete four visits receiving cTBS paired with placebo, lorazepam (LZP), or baclofen (BAC). All drugs are FDA-approved and administered as single oral doses timed to peak plasma concentration approximately two hours prior to cTBS.

TMS-EEG provides the primary measurement approach. TMS-evoked potentials (TEPs) are scalp-recorded electrical responses to individual TMS pulses that reflect summated excitatory and inhibitory postsynaptic activity from stimulated neuronal populations. Characteristic peaks are named by polarity and latency: P30 and P60 reflect glutamatergic excitatory transmission, N45 reflects GABA-A-mediated inhibitory tone, and N100 reflects GABA-B-mediated inhibitory tone. Up to 200 single TMS pulses are delivered per TEP session at the individualized dlPFC target. TEPs are acquired at several timepoints each visit. cTBS consists of 600 pulses delivered at 80% of resting motor threshold.

TMS is delivered using the Nexstim NBS-6 system with integrated real-time neuronavigation, with targeting based on individual structural MRI acquired prior to experimental visits.

The central hypothesis is that cTBS reduces P30 amplitude through LTD-like synaptic depression driven by NMDAR activation and consequent AMPA receptor internalization. Under this hypothesis, DCS will enhance and memantine will block the post-cTBS reduction in P30, without corresponding changes in N45 or N100. If instead GABAergic mechanisms contribute, cTBS will increase N45 and/or N100 amplitude, with additive effects from lorazepam and baclofen respectively. The design allows estimation of relative contributions from each receptor system.

A functional measure of dlPFC network integration, the N-back working memory task, is administered before and after cTBS at each visit. Resting-state fMRI acquired at baseline is used for exploratory post-hoc correlations with TEP outcomes and EEG source localization. Peripheral blood is collected for drug plasma quantification, and saliva samples are collected for BDNF Val66Met genotyping.

Statistical analysis uses a linear mixed model with Drug Type, TMS Type (active vs. sham), and Time (pre-drug, post-drug/pre-cTBS, post-cTBS) as within-subject factors, including all two- and three-way interactions, with relevant demographic and clinical covariates. The study is powered to detect a moderate effect size (Hedges' g = 0.5) with 80% power at α = 0.05, requiring 31 completers per aim. Enrollment targets 35 completers per aim, with up to 80 participants enrolled to account for attrition.

03

Conditions studied

  • Major Depression

Keywords

  • TMS
  • EEG
  • TMS-EEG
  • Depression
  • Pharmacologic Augmentation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Can safely receive TMS and study drugs
  • Stable medication regimen for one month prior to study participation, and for the duration of the study
  • Not currently receiving TMS, ECT, or ketamine
  • No active safety concerns related to suicidality
  • Moderate to severe Major Depressive Disorder as indicated by the Patient Health Questionnaire or Quick Inventory of Depressive Symptomatology

Exclusion criteria

Exclusion Criteria:

  • History of seizures or epilepsy
  • History of intracranial pathology or lesions from any etiology
  • History of traumatic brain injury including prolonged loss of consciousness more than 15 min
  • Signs of increased intracranial pressure
  • Any major neurological conditions (ex: recent stroke, tumor, neurodegenerative disorders, etc.)
  • Major medical conditions that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.)
  • Severe migraines that may result in treatment intolerance.
  • Inability to tolerate MRI.
  • Pregnancy
  • Known allergic reaction to d-cycloserine, baclofen, memantine, or lorazepam
05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Sham comparator
    Sham + Placebo

    Sham TMS and placebo drug

    Device: Transcranial Magnetic Stimulation Sham · Drug: Placebo

  • Placebo comparator
    TMS + Placebo

    Active TMS and placebo drug

    Device: Continuous theta-burst stimulation (cTBS) · Drug: Placebo

  • Experimental
    NMDAR Antagonism

    Active TMS and memantine

    Device: Continuous theta-burst stimulation (cTBS) · Drug: Memantine

  • Experimental
    NMDAR Agonism

    Active TMS and d-cycloserine

    Drug: D-Cycloserine (DCS) · Device: Continuous theta-burst stimulation (cTBS)

  • Experimental
    GABA-A Agonsim

    Active TMS and lorazepam

    Device: Continuous theta-burst stimulation (cTBS) · Drug: Lorazepam (drug)

  • Experimental
    GABA-B Agonism

    Active TMS and baclofen

    Device: Continuous theta-burst stimulation (cTBS) · Drug: Baclofen

Interventions

  • DrugCycloserineStudies of CycloserineCycloserine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    D-cycloserine 100 mg is administered as a single oral dose approximately two hours prior to cTBS, timed to peak plasma concentration. At this dose, DCS acts as a partial agonist at the glycine co-agonist site of the NMDA receptor, facilitating NMDAR-mediated synaptic transmission. It is used in Aim 1 to test whether NMDAR agonism enhances cTBS-induced LTD-like plasticity at the dlPFC.

  • DeviceContinuous theta-burst stimulation (cTBS)

    Continuous theta-burst stimulation is delivered using the Nexstim NBS-6 system with integrated real-time neuronavigation. The cTBS protocol consists of 600 pulses delivered at 80% active motor threshold, targeting the left dorsolateral prefrontal cortex (dlPFC) localized to individual structural MRI.

    Also known as: cTBS, TMS, Transcranial magnetic stimulation

  • DeviceTranscranial Magnetic Stimulation Sham

    Sham TMS is delivered using an identical coil that produces the same auditory and somatosensory scalp sensation as active stimulation without inducing a significant cortical response. The stimulation protocol will be the same as the active cTBS protocol.

    Also known as: Sham TMS

  • Memantine 10 mg is administered as a single oral dose approximately two hours prior to cTBS. Memantine is a non-competitive NMDA receptor antagonist acting at the phencyclidine site within the receptor channel. It is used in Aim 1 to test whether NMDAR antagonism blocks cTBS-induced LTD-like plasticity at the dlPFC.

  • DrugLorazepamStudies of LorazepamLorazepam pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Lorazepam 1 mg is administered as a single oral dose approximately two hours prior to cTBS, timed to peak plasma concentration. Lorazepam is a positive allosteric modulator at GABA-A receptors, increasing chloride influx and membrane hyperpolarization. It is used in Aim 2 to test whether GABA-A receptor potentiation enhances cTBS-induced inhibition at the dlPFC.

  • Baclofen 50 mg is administered as a single oral dose approximately one hour prior to cTBS, timed to peak plasma concentration. Baclofen is a GABA-B receptor agonist that suppresses presynaptic neurotransmitter release from both GABAergic interneurons and glutamatergic neurons. It is used in Aim 2 to test whether GABA-B receptor agonism enhances cTBS-induced inhibition at the dlPFC.

  • DrugPlacebo

    Sucrose packaged in identical cellulose capsules, administered orally.

06

What researchers measure

Primary outcomes

  1. Change in P30 TEP Peak Amplitude

    Change in P30 TMS-evoked potential peak amplitude measured via simultaneous 64-channel EEG in response to single-pulse TMS delivered at the left dlPFC. P30 amplitude reflects AMPA receptor-mediated glutamatergic excitatory transmission and is the primary index of LTD-like synaptic depression induced by cTBS. Change is assessed between post-drug/pre-cTBS and post-cTBS timepoints, and relative to the sham+placebo condition.

    Time frame: Measured at 4 timepoints within each study visit: pre-drug baseline, approximately 2 hours post-drug administration (immediately prior to cTBS), and approximately 5 and 20 minutes post-cTBS. Visits separated by at least 1 week.

  2. Change in N45 TEP Peak Amplitude

    Change in N45 TMS-evoked potential peak amplitude measured via simultaneous 64-channel EEG. N45 amplitude reflects GABA-A receptor-mediated inhibitory transmission. In Aim 1, N45 serves as a specificity control - changes are not expected with NMDAR-targeting drugs. In Aim 2, N45 is a primary index of whether cTBS engages GABA-A-mediated inhibition, and whether lorazepam produces additive inhibition post-cTBS.

    Time frame: Measured at 4 timepoints within each study visit: pre-drug baseline, approximately 2 hours post-drug administration (immediately prior to cTBS), and approximately 5 and 20 minutes post-cTBS.

  3. Change in N100 TEP Peak Amplitude

    Change in N100 TMS-evoked potential peak amplitude measured via simultaneous 64-channel EEG. N100 amplitude reflects GABA-B receptor-mediated inhibitory transmission. In Aim 1, N100 serves as a specificity control alongside N45. In Aim 2, N100 is a primary index of whether cTBS engages GABA-B-mediated inhibition, and whether baclofen produces additive inhibition post-cTBS.

    Time frame: Measured at 4 timepoints within each study visit: pre-drug baseline, approximately 2 hours post-drug administration (immediately prior to cTBS), and approximately 5 and 20 minutes post-cTBS.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Rossi S, Antal A, Bestmann S, Bikson M, Brewer C, Brockmoller J, Carpenter LL, Cincotta M, Chen R, Daskalakis JD, Di Lazzaro V, Fox MD, George MS, Gilbert D, Kimiskidis VK, Koch G, Ilmoniemi RJ, Lefaucheur JP, Leocani L, Lisanby SH, Miniussi C, Padberg F, Pascual-Leone A, Paulus W, Peterchev AV, Quartarone A, Rotenberg A, Rothwell J, Rossini PM, Santarnecchi E, Shafi MM, Siebner HR, Ugawa Y, Wassermann EM, Zangen A, Ziemann U, Hallett M; basis of this article began with a Consensus Statement from the IFCN Workshop on "Present, Future of TMS: Safety, Ethical Guidelines", Siena, October 17-20, 2018, updating through April 2020. Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines. Clin Neurophysiol. 2021 Jan;132(1):269-306. doi: 10.1016/j.clinph.2020.10.003. Epub 2020 Oct 24. PubMed 33243615 ↗
  • Ganesh P, Kweon J, Siddiqi SH, Carpenter LL, Brown JC. Comparing synaptic mechanisms of iTBS and 10-Hz rTMS corticomotor plasticity. Transcranial Magn Stimul. 2025 Dec;5:100191. doi: 10.1016/j.transm.2025.100191. Epub 2025 Aug 26. PubMed 41341503 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data will be shared through the National Institute of Mental Health Data Archive (NDA) in accordance with NIMH data sharing expectations. Data to be shared will include demographic information, clinical scale scores, and TMS-EEG outcome data. Data will be submitted to the NDA following standard de-identification procedures and will be made available to qualified researchers through the NDA data access request process.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: Data will be submitted to the NDA within 1 year of primary study completion or upon publication of primary results, whichever comes first.

Access criteria: Data will be accessible to qualified researchers through the NIMH Data Archive data access request process.

Data sharing details ↗ · nda.nih.gov

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2030, 57 months after the start.

Of 49 non-industry phase 1 interventional studies under Depressive Disorder, Major, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 16. This study's planned 57 months is above that.

Counting every sponsor, half of 89 studies reached it within 16 months; a quarter within 5 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2026
First posted
May 1, 2026
StartActual
Mar 11, 2026
Primary completionEst.
Dec 2030
CompletionEst.
Dec 2030
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07560878
Lead sponsor
Mclean Hospital
Responsible party
Joshua C. Brown, MD, PhD (Director, TMS Research, Mclean Hospital) — Principal investigator
First posted
May 1, 2026
Start date
Mar 11, 2026
Primary completion
Dec 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
May 13, 2026

Study contacts

Prem Ganesh, MS
Contact
pganesh@mgb.org
617-855-2153
Dennis W Guevara
Contact
dguevara@mclean.harvard.edu
617-855-2340
Joshua C Brown, MD, PhD
principal investigator · Mclean Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cycloserine · Memantine · Lorazepam · Baclofen

Start the discussion